- Home
- VRCA vs NRXP Comparison
VRCA vs NRXP Comparison
Compare VRCA & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | NRXP |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.5M | 99.2M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | VRCA | NRXP |
|---|---|---|
| Price | $6.26 | $4.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $17.00 | ★ $38.25 |
| AVG Volume (30 Days) | 38.9K | ★ 867.3K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | N/A |
| Revenue This Year | N/A | $2,547.84 |
| Revenue Next Year | $94.44 | $1,591.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 370.22 | N/A |
| 52 Week Low | $0.72 | $1.65 |
| 52 Week High | $9.82 | $5.06 |
Technical Indicators
Market Signals| Indicator | VRCA | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 58.88 |
| Support Level | $5.32 | $1.83 |
| Resistance Level | $6.56 | $4.20 |
| Average True Range (ATR) | 0.55 | 0.32 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 59.02 | 92.64 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.